ORIGINAL RESEARCH ARTICLE
O bservational studies have identified associations between adiposity and the risk of developing incident coronary heart disease (CHD), stroke, and type 2 diabetes mellitus (T2D). 1, 2 Many observational studies report consistent results with different measures of adiposity; for example, the Emerging Risk Factors Collaboration found similar associations with both general adiposity measured via body mass index (BMI) and central adiposity measured via waist-to-hip ratio (WHR) for CHD and ischemic stroke. 1 The association of different adiposity measures with T2D has also been found to be similar. 2 However, other studies have suggested that central adiposity, measured as either WHR or waist circumference, may have stronger associations with cardiovascular disease. For example, INTERHEART found a stronger association for WHR with myocardial infarction than BMI, and the association of WHR with myocardial infarction persisted after adjustment for BMI. 3 The Million Women Study found that waist circumference associated with an increase in CHD risk within BMI categories (and vice versa), again suggesting that each is independently associated with CHD. 4 Furthermore, INTERSTROKE found WHR to be more strongly associated with stroke risk than BMI. 5 Although these studies have attempted to separate the independent effects of general and central adiposity, this remains challenging in observational studies because of the high degree of correlation between adiposity measures. Another problem is that adiposity measures may differ in their reproducibility; for example, BMI is less affected by regression dilution bias, a bias to the null resulting from measurement error, than WHR. 6 In addition, all measures of adiposity suffer from confounding attributable to underlying ill health at low or subclinical levels, because many chronic conditions lead to weight loss. [7] [8] [9] Consequently, it is very difficult, if not impossible, to quantify the true independent effects of different measures of adiposity in observational studies alone.
Although Mendelian randomization (MR) studies minimize bias from traditional sources such as confounding, regression dilution bias, and reverse causation, they may be susceptible to bias from pleiotropy (association of genetic variants with >1 variable). Pleiotropy can be vertical because of the multiple downstream effects that follow the single-nucleotide polymorphism (SNP) effect on the exposure of interest, but this does not compromise MR assumptions. Alternatively, pleiotropy can be horizontal, whereby the SNP or instrument affects pathways other than those of the exposure of interest and could therefore invalidate the MR assumption that the SNP only affects the outcome through the exposure of interest, potentially leading to biased causal estimates. With multi-SNP instruments, there is a chance that pleiotropic effects might become balanced such that causal inference regarding the exposure is possible. In this study, we perform MR analyses of BMI and WHR together with recently developed methods that are robust to horizontal pleiotropy under additional assumptions (online-only Data Supplement Figure I ). We therefore use MR-Egger regression to provide a test for unbalanced horizontal pleiotropy and a causal estimate of exposure on outcome in its presence. 10, 11 In addition, we use the weighted median estimator that can give valid estimates even in the presence of horizontal pleiotropy provided at least 50% of the information in the analysis comes from variants that are valid instruments, and has the advantage of retaining greater precision in the estimates than MR-Egger. 12 This article represents the most comprehensive assessment of the causal role of adiposity on CHD, stroke, and T2D to date. It contrasts the causal effects of central adiposity (WHR adjusted for BMI [WHRadjBMI] ) from general adiposity (BMI) on multiple cardiovascular outcomes: new CHD events from 14 prospective studies/ randomized controlled trials in addition to data publicly
Clinical Perspective
What Is New?
• This large-scale genetic analysis presents the most comprehensive causal assessment of adiposity with cardiometabolic diseases to date, including new data for stroke subtypes from METASTROKE and novel cardiometabolic traits including ECG measures and carotid intima media thickness.
• We find that waist-to-hip ratio adjusted for body mass index, a measure of central body fat distribution that aims to be independent of general adiposity, is causally related to higher risks of coronary heart disease, ischemic stroke, and a multitude of cardiometabolic traits.
• Our findings also reinforce existing evidence on the causal relevance of general adiposity (body mass index) to these diseases and provide more precise estimates.
What Are the Clinical Implications?
• Both the amount of adiposity and its distribution play important roles in influencing multiple cardiometabolic traits and the development of cardiometabolic diseases.
• Furthermore, our findings indicate that body fat distribution has multiple causal roles in disease that are independent of general adiposity.
• This suggests that physicians should pay attention to measures of adiposity beyond body mass index, because measurement of such traits may identify patients at risk of cardiometabolic disease and provide opportunities to the scientific community to identify novel approaches to disease prevention. 13 increasing CHD cases to 66 842, multiple stroke subtypes using data from METASTROKE, 14 and T2D from DIAGRAM (Diabetes Genetics Replication and Meta-analysis). 15 We present the largest number of cardiometabolic traits ever examined in a MR analysis of adiposity including lipids from the Global Lipids Genetic Consortium (GLGC; 213 500 participants) 16 and many novel intermediate disease end points, including ECG measures of left ventricular hypertrophy, carotid intima media thickness as a measure of subclinical atherosclerosis, and markers of renal and lung disease, as well. We build distinct multi-SNP genetic instruments for each adiposity measure using the most comprehensive repertoire available from recent genome-wide association studies (GWAS), 17, 18 with 97 SNPs for BMI and 49 SNPs for WHRadjBMI, thereby more than doubling the phenotypic variance explained in some earlier MR studies.
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METHODS
Study Selection and Inclusion of Participants
We include individual participant data from 10 studies in the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) consortium (see online-only Data Supplement Table I 
Clinical Outcomes
Online-only Data Supplement Table II provides details of CHD ascertainment and number of events by study. In UCLEB studies, the primary outcome was combined prevalent or incident CHD defined as fatal or nonfatal myocardial infarction, or a coronary revascularisation procedure, but excluding angina. In the majority of studies, events were validated (eg, hospital episode statistics, clinical/laboratory measurements, review of primary care medical records). CARDIoGRAMplusC4D used standard criteria for defining cases of coronary artery disease and myocardial infarction with some studies including angiography-confirmed stenosis and stable or unstable angina. 13 METASTROKE defined stroke as a typical clinical syndrome with radiological confirmation; subtyping was done with the TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification system. 14 We include all ischemic stroke, 3 subtypes of ischemic stroke (large-vessel disease, small-vessel disease, and cardioembolic stroke) and hemorrhagic stroke. T2D definitions follow DIAGRAM. 24 
Cardiometabolic Traits
For analysis of individual participant data studies, data on sex, age, measured standing height, weight, waist circumference, and hip circumference were used to derive BMI and WHRadjBMI traits. WHRadjBMI was calculated by generating the predicted residuals from the linear regression of WHR on BMI. Biomarkers included in analyses were grouped into the following categories: lipids (triglycerides, high-density lipoprotein cholesterol [HDL-C], and low-density lipoprotein cholesterol [LDL-C), inflammation (interleukin 6), lung function (ratio of forced expiratory volume in 1 second to forced vital capacity), metabolic (glucose, insulin, and albumin), renal (creatinine, estimated glomerular filtration rate, modification of diet in renal disease equation), and systolic blood pressure. The following ECG measures of left ventricular hypertrophy were recorded: QRS voltage sum, QRS voltage sum product, Cornell product, and Sokolow-Lyon index, and PR interval, as well (see online-only Data Supplement Method I for definitions). Cardiometabolic traits that were not normally distributed were transformed to the natural logarithmic scale. For comparability across biomarkers, measurements were z-score standardized. Self-reports of current smoking status (ever/ never) and alcohol consumption (drinker/nondrinker) were considered to be potential confounders of adiposity-cardiovascular disease (CVD) associations.
Genotyping
Online-only Data Supplement Table I details genotyping by study. Genotyping in all UCLEB studies was conducted with the Metabochip array (except a subset of ELSA study [English Longitudinal Study of Ageing] that used a GWAS array). 25 The remaining studies used GWAS arrays (HRS, PROSPER) or Exome Chip (NEO). Individuals were excluded from the analyses on the basis of sex mismatch, excessive or minimal heterozygosity, relatedness or individual missingness (>3%). Individuals of non-European ancestry were removed to minimize confounding by population structure. SNPs with a low call rate or evidence of departure from Hardy-Weinberg equilibrium were excluded from analyses (see online-only Data Supplement Table I for thresholds used in different studies).
Statistical Analyses
Observational Analyses
In individual participant data studies, adiposity (BMI or WHRadjBMI) was z-score standardized, and linear or logistic regression models were fitted for each cardiometabolic trait or disease outcome. Observational models were adjusted for age and sex. Fixed-effect meta-analyses were used to derive combined observational estimates across studies. We calculated I 2 statistics to quantify heterogeneity between studies and derived P values from the Cochran Q test. 26 
GENETIC ANALYSES SNP Selection and Construction of the Genetic Instruments
Selection of SNPs for the genetic instruments was based on analyses from the GIANT consortium (Genetic Investigation of Anthropometric Traits), which included 339 224 individuals from 125 separate studies for BMI 17 and 224 459 individuals from 101 studies for WHRadjBMI. 18 These studies identified 97 independent SNPs for BMI and 49 independent SNPs for WHRadjBMI at GWAS significance. We found no overlap between the BMI SNPs and WHRadjBMI SNPs. In studies where the SNP identified by GIANT was not available in the Metabochip array, we used proxy SNPs in linkage disequilibrium (R 2 >0.8) with the specified SNP. Details of proxy SNPs used by platform (Metabochip/GWAS) are given in onlineonly Data Supplement Tables III and IV.
Genetic Association Analyses in Individual Participant Data
We performed a within-study genetic association analysis with adiposity (standardized BMI and WHRadjBMI) as a continuous trait using an additive model. We used linear or logistic regression models to estimate the additive effect of each SNP on cardiometabolic traits and outcomes. We used logistic regression to test the association of each SNP with smoking and alcohol consumption as potential confounders of the adiposity-CVD association.
Instrumental Variable Analyses in Summary Data
We conducted 3 tests for the causal estimation of each adiposity measure on cardiometabolic outcomes: (1) inverse variance-weighted (IVW) method, (2) MR-Egger, and (3) weighted median. In the absence of unbalanced horizontal pleiotropy, we would expect all three tests to give consistent results. All inverse variance (IV) estimates in summary data were calculated using the mrrobust package 27 in Stata version 14. 28 The proportion of variance in adiposity explained by the genetic instruments in summary data was calculated using the grs.summary function from the gtx package in R.
29, 30 A threshold of statistical significance of P<0.025 (0.05/2=0.025) was used to reflect testing for 2 different adiposity traits (BMI and WHRadjBMI).
IVW Instrumental Variable Analyses
To combine data across studies with summary level data, we pooled the association of each SNP on risk of each CVD outcome/cardiometabolic trait using fixed-effects meta-analysis. To provide external weights for the SNPadiposity associations, the effect of each SNP on adiposity (BMI; WHRadjBMI) in GIANT was pooled with that in all other contributing studies, excluding studies that had already contributed to GIANT (1958BC, EAS, HRS, NSHD, PROSPER, Whitehall II). To quantify heterogeneity in the SNP effects across studies, we calculated I 2 and derived P values from the Cochrane Q tests. All P values were 2-sided. IVW meta-analysis was used to provide a combined estimate of the causal estimates (SNP-outcome/SNP-adiposity) from each SNP. IVW is equivalent to a 2-stage least-squares or allele score analysis using individual-level data, and is hence referred to here as conventional MR. 31 However, it can lead to overrejection of the null, particularly when there is heterogeneity between the causal estimates from different genetic variants.
MR-Egger Instrumental Variable Analyses
To account for potential unbalanced horizontal pleiotropy in the multi-SNP adiposity instruments, we reestimated the instrumental variable associations using MREgger regression.
10,11 MR-Egger tests for the presence of, and accounts for, unbalanced horizontal pleiotropy by introducing a parameter for this bias. 10 Specifically, linear regression of the instrument-outcome effects is performed on the instrument-exposure effects, with the slope representing the causal effect estimate and the intercept representing the net bias attributable to horizontal pleiotropy. An assumption is required that the individual SNP effects on the exposure are independent of their pleiotropic effects on the outcome (termed the InSIDE assumption). 12 
Weighted Median Estimate Instrumental Variable Analyses
Finally, we applied a complementary approach termed the weighted median estimator that can give valid estimates even in the presence of unbalanced horizontal pleiotropy, provided at least half of the weighted variance is valid. 12 
Power Calculations
Power to detect causal estimates was calculated based on the proportion of variance of the exposure explained by the instruments (R 2 ), the total number of individuals in the analysis, and the number of cases and controls using the online tool.
32, 33 Power estimates are provided in online-only Data Supplement Table V) .
RESULTS
Studies and Participants
Full descriptive details of the included studies are given in online-only Data Supplement Table I . Data from 14 prospective studies and randomized trials and 4 consortia were included with 66 842 CHD cases (3716 from UCLEB/other nonconsortia studies), 12 389 ischemic stroke cases, and 34 840 T2D cases. The number of individuals included in the analyses of cardiometabolic traits ranged from 6625 to 213 556. The mean age in individual participant data studies was 63.5 years, the mean BMI was 27.4 kg/m 2 (SD 4.6), and the mean WHR was 0.89 (SD 0.13) (online-only Data Supplement Tables  I and VI) . Distribution of binary traits by study are given in online-only Data Supplement Figure 1A and 1B presents estimates of associations between BMI and WHRadjBMI with cardiometabolic traits from IV analyses. Both genetically instrumented adiposity measures were found to be causally associated with increased insulin and triglycerides. In addition, BMI was causally associated with higher interleukin 6, with a directionally consistent result identified for WHRadjBMI. Both adiposity measures were also causally associated Nonnormally distributed variables were natural ln transformed; therefore, mean differences displayed on the log scale may be antilogged and interpreted as percentage differences in SD of trait per SD in BMI. Log triglycerides from individual participant data studies only; GLGC triglycerides in online-only Data Supplement Table X. B, Association of WHRadjBMI with continuous biomarkers derived from Mendelian randomization analysis. Values represent standardized mean differences of each trait per SD increase in WHRadjBMI derived from conventional (IVW) Mendelian randomization analysis. Nonnormally distributed variables were natural log transformed; therefore, mean differences displayed on the log scale may be antilogged and interpreted as percentage difference in SD of trait per SD in WHRadjBMI. Log triglycerides from individual participant data studies only; GLGC triglycerides in online-only Data Supplement Table XI . BMI indicates body mass index; EGFR, estimated glomerular filtration rate; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GLCG, Global Lipids Genetic Consortium; HDL-C, high-density lipoprotein cholesterol; IL6, interleukin 6; IMT, intima-media thickness; IVW, inverse-variance weighted; LDL-C, low-density lipoprotein cholesterol; MDRD, modification of diet in renal disease; SBP, systolic blood pressure; SD, standard deviation; and WHRadjBMI, waist-to-hip ratio adjusted for body mass index.
MR Analysis of Adiposity With Cardiometabolic Traits
with decreased levels of HDL-C. However, only WHRadjBMI was associated with increased LDL-C, and the association with systolic blood pressure was also stronger. BMI was inversely associated with albumin, whereas WHRadjBMI was not; but heterogeneity across studies was moderately high (I 2 =57%). There was evidence for a causal association with some of the ECG measures that index left ventricular hypertrophy with both adiposity measures associated with higher log Cornell Product; in addition BMI, but not WHRadjBMI, associated with a lower Sokolow-Lyon index. There was no suggestion for a causal association of either measure of adiposity and PR interval.
Both WHRadjBMI and, to a weaker extent, BMI were causally associated with higher carotid intima media thickness (39%; 95% confidence interval [CI], 9%-77% and 18%; 95% CI, 1%-38% higher per SD in WHRadjBMI and BMI, respectively). WHRadjBMI had a weak association with lung function (forced expiratory volume in 1 second:forced vital capacity) at 0.12 U per SD (95% CI, 0.00-0.23), but the P value does not meet the threshold that takes into account testing for multiple measures of adiposity. There was no suggestion of a causal association of either adiposity measure with any of the measures of renal function.
With MR-Egger regression, there was no convincing evidence for unbalanced horizontal pleiotropy in any of the associations of adiposity traits with continuous cardiometabolic traits (online-only Data Supplement Tables  X and XI) .
Online-only Data Supplement Figure IIA and IIB illustrate the consistency of observational and IV estimates for associations between adiposity and cardiometabolic traits (online-only Data Supplement Tables XII and XIII). Figure 2A through 2C shows the association of each adiposity measure with CHD, ischemic stroke, and T2D from conventional IVW and weighted median MR analyses. MREgger estimates tended to be much more imprecise and are therefore presented separately in online-only Data Supplement Table XIV to facilitate interpretation.
MR Analysis of Adiposity With Cardiometabolic Diseases
MR Analysis of Adiposity With CHD
The summary causal estimate per 1 SD increment in BMI from conventional IVW MR was an OR for CHD of 1.36 (95% CI, 1.22-1.52) (Figure 2A ). MR-Egger regression suggested little evidence for unbalanced horizontal pleiotropy in the genetic instrument (intercept P value=0.65), and both MR-Egger and weighted median estimates were consistent with the IVW estimate (online-only Data Supplement Figure IIIA) . Furthermore, MR estimates were consistent with observational estimates reported by the Emerging Risk Factors Collaboration (Figure 2A) Similarly, we found an association between WHRadjBMI and CHD using conventional MR (OR, 1.48; 95% CI, 1.28-1.71 per SD WHRadjBMI, Figure 2A and online-only Data Supplement Figure IIIB) . The intercept for the MR-Egger test was 0.0134 (95% CI, -0.0004 to 0.0278; P=0.06). The causal estimate from MR-Egger was imprecise (OR, 0.89; 95% CI, 0.52-1.53), but the weighted median estimator (which retains more power than MR-Egger) provided a causal effect of 1.61 (95% CI, 1.36-1.90) which was consistent with the IVW result.
MR Analysis of Adiposity With Ischemic Stroke
The causal OR for the association between BMI and ischemic stroke was 1.09 (95% CI, 0.93-1.28 per SD) ( Figure 2B) . Results from the MR-Egger analysis were compatible with no unbalanced horizontal pleiotropy (intercept P value=0.73), and the weighted median estimator suggested no causal association (online-only Data Supplement Figure IIIC) . Estimates for association between BMI and stroke subtypes were imprecise and 95% CIs all included the null (Table) . Thus, whereas all IV estimates for BMI and stroke include the Emerging Risk Factors Collaboration estimate ( Figure 2B ), lack of precision hinders any clear causal evidence for an association between BMI and ischemic stroke.
Results do, however, provide some evidence for a causal association of WHRadjBMI with ischemic stroke (OR, 1.32; 95% CI, 1.03-1.70 per SD in WHRadjBMI) ( Figure 2B ). MR-Egger regression was consistent with no unbalanced horizontal pleiotropy (intercept P value=0.94), and the weighted median estimator was very close to the IVW estimate (causal OR, 1.34; 95% CI, 0.97-1.86 per SD increase in WHRadjBMI) (onlineonly Data Supplement Figure IIID) . Limited evidence was found for a causal association with stroke subtypes; all point estimates were consistently >1, but precision was poor and 95% CIs included the null (Table) .
MR Analysis of Adiposity With T2D
We found a causal OR for T2D of 1.98 (95% CI, 1.41-2.78) per SD increase in BMI ( Figure 2C ). Similar but stronger estimates were identified using MR-Egger (OR, 3.70; 95% CI, 1.63-8.41; P value for pleiotropy=0.10) and weighted median estimator (OR, 2.70; 95% CI, 2.26-3.23). One BMI SNP (rs7903146) was an outlier (online-only Data Supplement Figure IIIe) and is a marker for the TCF7L2 gene, a GWAS-identified locus for T2D. 34 We therefore repeated the T2D analysis excluding rs7903146 (online-only Data Supplement Figure 2C ). MR-Egger did not provide evidence of unbalanced horizontal pleiotropy (P value for pleiotropy=0.21), and the weighted median estimator result was consistent with the IVW (OR, 1.64; 95% CI, 1.25-2.15) (online-only Data Supplement Figure IIIG) .
Multivariate MR
We found some evidence for association of both adiposity instruments with smoking, but not with other major confounders (online-only Data Supplement Table XVI). To account for this, sensitivity analyses were undertaken A, Associations of adiposity with risk of CHD from observational and Mendelian randomization analyses. Association between adiposity (BMI and WHRadjBMI) and coronary heart disease, comparing causal odds ratios (OR) per SD of adiposity trait derived from instrumental variable analysis and observational analysis from the Emerging Risk Factors Consortium hazard ratio (HR per SD of BMI or waist:hip adjusted for age, sex, and smoking status). 1 Causal estimates are derived from Mendelian randomization and include conventional (ratio) approach and weighted median (see Methods for further details). P(genetic pleiotropy) relates to the P value derived from the intercept of MR-Egger; a small P value denotes the presence of unbalanced horizontal pleiotropy. B, Associations of adiposity with risk of ischemic stroke from observational and Mendelian randomization analyses. Association between ischemic stroke and adiposity (BMI and WHRadjBMI) comparing causal odds ratios (OR) per SD of adiposity trait derived from instrumental variable analysis and observational analysis from the Emerging Risk Factors Consortium (HR of ischemic stroke per SD of BMI or waist:hip adjusted for age, sex, and smoking status). 1 Causal estimates are derived from Mendelian randomization and include conventional (ratio) approach and weighted median (see Methods for further details). P(genetic pleiotropy) relates to the P value derived from the intercept of MR-Egger; a small P value denotes presence of unbalanced horizontal pleiotropy. C, Associations of adiposity with risk of T2D from observational and Mendelian randomization analyses. Association between T2D and adiposity (BMI and WHRadjBMI) comparing causal odds ratios (OR) per SD of adiposity trait derived from instrumental variable analysis and observational analysis from Vazquez et al. 2 Causal estimates are derived from Mendelian randomization and include conventional (ratio) approach and weighted median (see Methods for further details). P(genetic pleiotropy) relates to the P value derived from the intercept of MR-Egger; a small P value denotes presence of unbalanced horizontal pleiotropy. BMI indicates body mass index; CHD, coronary heart disease; CI, confidence interval; ERFC, Emerging Risk Factors Consortium; HR, hazard ratio; IVW, inverse-variance weighted; SD, standard deviation; T2D, type 2 diabetes mellitus; WHR, waist-to-hip ratio; and WHRadjBMI, waist-to-hip ratio adjusted for body mass index.
for each cardiometabolic disease using multivariate MR, including the effect of each SNP used as an instrument for BMI and WHRadjBMI on smoking. MR estimates were found to be robust to this adjustment (online-only Data Supplement Table XVII), with generally consistent point estimates measured with greater imprecision, reflecting the reduced power in these analyses. The multivariate MR (adjusted for smoking) for the causal association of WHRadjBMI with ischemic stroke was 1.27 (95% CI, 0.84-1.93) broadly similar to 1.32 (95% CI, 1.03-1.70) in the main IVW analysis, but with a wider CI. We also included the forced expiratory volume in 1 second to forced vital capacity ratio in these sensitivity analyses because of the likely association of this trait with smoking; again, adjusted results were very similar to the main IVW results (online-only Data Supplement Table XVII) .
DISCUSSION
We conducted the most comprehensive MR analysis to date comparing the causal role of central and general adiposity in the development of multiple CVD outcomes (CHD, multiple stroke subtypes, and T2D). Owing to benefits of MR to minimize residual confounding by common lifestyle factors and underlying ill health, we are able to quantify that 1 SD increase in genetically instrumented WHRadjBMI (≈0.08 U) results in a ≈50% increase in risk of CHD independent of BMI. This compares with the ≈40% increase in risk of CHD we find per 1 SD increase in genetically instrumented BMI (≈4.6 kg/m 2 ), which is consistent with the observational effect derived from large prospective population cohorts including the Emerging Risk Factors Collaboration 1 (CHD hazard ratio, 1.29 [1.22-1.37] per 1 SD) and the Prospective Studies Collaboration. 34 Thus, although observational studies such as the Emerging Risk Factors Collaboration have found risk to be consistent across different measures of adiposity, our results suggest WHRadjBMI may have a stronger effect, although the greater imprecision in the MR estimates should also be considered.
Similarly, although observational studies have found that different measures of adiposity have similar associations with risk of ischemic stroke, 1 our results again suggest that WHRadjBMI may be more strongly associated (increased risk ≈30% per 1 SD). Recent findings from INTERSTROKE also suggest that WHR is a much stronger deleterious risk factor for ischemic stroke. 5 Our systolic blood pressure results follow a similar pattern, with a much stronger association between central adiposity and systolic blood pressure than general adiposity. This is also the first MR study to suggest potential causal association between central adiposity and carotid intima media thickness, a widely used surrogate measure of subclinical atherosclerosis.
Previous adiposity MR studies used limited numbers of SNPs (with weaker genetic instruments), fewer events, and generally failed to find evidence for a causal association between BMI and CHD. 19, 21 However, 1 MR study using a 3-SNP allele score (FTO, MC4R, TMEM18) reported an OR of 1.52 (95% CI, 1.12-2.05 for a 4 kg/ m 2 increase in BMI, 20 and, most recently, a MR study using a 32-SNP instrument for BMI found results for CHD similar to ours. 22 We do not, however, replicate the CI indicates confidence interval; and OR, odds ratio. *IVW refers to the inverse variance weighted (also termed conventional Mendelian randomization) and weighted median. †P(genetic pleiotropy) relates to the P value derived from the intercept of Mendelian randomization-Egger; a small P value denotes the presence of unbalanced horizontal pleiotropy.
causal association between BMI and ischemic stroke reported by the same study (hazard ratio per SD increase of BMI, 1.83; 95% CI, 1.05-3.20), 22 despite increasing the number of stroke cases 10-fold. Furthermore, our results are in line with those for ischemic stroke from the Emerging Risk Factors Collaboration and INTERSTROKE, including the apparently stronger association we find between central adiposity and stroke relative to general adiposity. Results for the causal association of WHRadjBMI with CHD and T2D are consistent with those from a recent MR analysis. 35 We present the largest number of cardiometabolic traits ever examined in a MR analysis of adiposity. The current findings are broadly consistent with earlier MR studies for glucose, triglycerides, HDL-C, systolic blood pressure, and interleukin 6, providing further support for a detrimental impact of adiposity on the cardiovascular system. 19, 21, 23 However, we find no evidence for a causal association between BMI and LDL-C, consistent with some but not all earlier studies. 21, 23 A recent MR study found a causal effect of BMI and a wide range of lipid metabolites, including all LDL metabolites, 36 but was conducted in a younger, healthier population (average BMI ≈24 kg/m 2 ) than is commonly included in MR studies (including the current one), and this could explain the discrepancy with our findings (because observational studies suggest the association of BMI and LDL-C plateaus beyond 27 kg/m 2 ). 34 We also report novel positive causal associations of adiposity with the ECG measure log Cornell product (a measure of left ventricular hypertrophy). The negative association of BMI with Sokolow-Lyon (an alternative measure of left ventricular hypertrophy) was unexpected and may represent a false positive. Although both log Cornell product and SokolowLyon measure left ventricular hypertrophy, log Cornell product is considered to be the better test for identifying left ventricular hypertrophy when measured against a gold standard. 37 This study demonstrates that central obesity (as quantified by WHRadjBMI) has a causal effect on CHD that is independent of BMI. This finding demonstrates the potential of MR approaches for investigating highly correlated adiposity measures that have proved challenging to disentangle in observational studies. 38 In these analyses, we find that WHRadjBMI has a more deleterious lipid profile than BMI, with detrimental associations of greater magnitude with triglycerides and HDL-C and association with LDL-C not found for BMI. The association of WHRadjBMI with carotid intima media thickness is also of greater magnitude. Conversely, BMI appears to have a greater inflammatory effect than WHRadjBMI, and potentially a stronger effect on the ECG measures that index left ventricular hypertrophy and with glucose and T2D, as well. The apparent lack of association of WHRadjBMI with glucose is surprising, but is potentially explained by a negative association of WHRadjBMI SNPs with BMI. Interestingly, a recent article showed WHRadjB-MI to associate with 2-hour fasting glucose, suggesting that WHRadjBMI may have differential effects according to how glucose is measured; different mechanisms are likely to regulate fasting and 2-hour glucose. 35 In keeping with our findings was the discovery that GWAS that identified 49 SNPs associated with WHRadjBMI 18 found associations of the SNPs with concentrations of HDL-C, triglycerides, LDL-C, adiponectin, and fasting insulin. Furthermore, the study identified enrichment of WHRadjBMI SNPs for T2D and CHD.
This study suggests that it is not only the volume of adiposity, but also its location, that is relevant for disease, lending weight to the emerging theory that the deposition of body fat plays important roles that are independent of total fat. For example, at a given BMI, there is considerable interindividual variation in the amount of visceral fat, which shows associations with disease. 39 Our results also suggest that efforts to quantify the effect of adiposity on burden of disease should include multiple measures of adiposity to avoid underestimating the true burden of adiposity on health. 40 Regarding specific interventions that focus on WHR more than BMI, there is observational evidence that physical activity can modify WHR independent of BMI. 41 Thus, it may be possible to mitigate the effects of WHR through increased population-wide physical activity. In addition, our findings open potentially new avenues of investigation. For example, identifying these causal effects of WHRadjBMI can enable research to focus on the downstream consequences of this trait, and potentially identify traits (such as metabolites) 35 that could mediate the relationship between WHRadjBMI and disease which may themselves be amenable to pharmacological modification. Such traits downstream of WHRadjBMI could be unique (and not shared with BMI), raising the possibility of novel opportunities for drug discovery and disease prevention.
Strengths
This study has many strengths. First, independent multi-SNP instruments comparing the effect of central and general adiposity on multiple CVD outcomes; second, the use of powerful genetic instruments for BMI and WHRadjBMI that explained up to twice the phenotypic variation in comparison with previous MR studies; third, large number of clinical events that provided ample power to detect the associations of adiposity with cardiometabolic diseases; fourth, the use of methods to minimize the impact of unbalanced horizontal pleiotropy in the genetic instruments that may invalidate findings from conventional MR.
In addition to this being the most comprehensive evaluation of adiposity-related traits with cardiovascular and metabolic risk factors and diseases, our analysis also facilitates their direct comparison, and therefore contrasts the effects of general adiposity with body fat distribution in the same data sets. This provides novel insights, demonstrating that WHRadjBMI is more relevant to the development of subclinical atherosclerosis and stroke than BMI, whereas both BMI and WHRadjBMI are important for CHD and T2D.
Limitations
Limitations include the potential pleiotropic effects of the multi-SNP instruments. However, results suggest little evidence for unbalanced horizontal pleiotropy. Reestimates of the causal associations using MR-Egger regression were broadly consistent with our conventional MR analysis, albeit with a loss of precision and, consequently, a loss of power, whereas weighted median estimates (that retain more power than MR-Egger) proved remarkably similar to IVW.
The InSIDE (Instrument Strength Independent of Direct Effect), which is untestable, assumes that the pleiotropic effects of the genetic variants are uncorrelated with the association of the genetic variants with the exposure. Violation of InSIDE would give rise to biased causal estimates from MR-Egger; however, each MR approach has different strengths and assumptions, for example, violation of InSIDE does not affect the weighted median MR approach. 12 This highlights the importance of using the 3 MR approaches (IVW, median, and MR-Egger) in our study. General concordance of MR estimates derived from these approaches helps reinforce the conclusions that can be drawn. We used a multi-SNP instrument for WHR that had already been adjusted for BMI as part of the GIANT GWAS. 18 Genetic instruments for phenotypes adjusted for heritable components may show association with the adjusted phenotype through collider bias, 42 which could violate the InSIDE assumption. Indeed, we found WHRadjBMI SNPs to be associated with BMI beyond what would be expected by chance (online-only Data Supplement Table XVIII ). This could lead to biased results; however, in the current scenario, the bias will tend to be toward the null (and underestimate the true effect) as the WHRadjBMI SNPs are associated negatively with BMI.
We selected cardiometabolic traits a priori on the basis that previous studies have shown them to be observationally and genetically associated with BMI. Therefore, although we test multiple outcomes, use of a conventional Bonferroni would overpenalize the interpretation.
Future studies should look to include emerging CVD outcomes such as heart failure and atrial fibrillation, and consider additional potential confounders. In addition, more stroke cases should be added to improve precision in these analyses, in particular, for multivariate MR analyses.
Given that our MR analysis on CHD was largely based on summary data, we were unable undertake more detailed investigations of the linear relationship between BMI or WHRadjBMI and risk of CHD or to explore the causal effects of very low levels of BMI or WHR on CHD. 43 These are important next steps to investigate, given the uncertainty regarding whether the U-shape association of BMI with disease reflects a true causal relationship, or whether it is an artifact from residual confounding and underlying ill health. The recent finding of a J-shaped (rather than U-shaped) association between BMI and mortality in healthy nonsmokers reinforces the likely role of artifact in this association. 44 Therefore, application of methods for nonlinear MR could help to determine the true optimal level of BMI for health. 45 However, such analyses would require access to individual participant data in all studies.
Finally, although we identify several downstream biological mechanisms by which general and central adiposity may mediate the effects on risk of CHD, these results should be considered as exploratory and further studies using adequate methodology for mediation analysis should be conducted, 46, 47 including the analysis of finer resolution for cardiometabolic traits, for example, using NMR metabolomics.
CONCLUSIONS
Our study supports evidence for a causal role of both central and general adiposity in risk of CHD and T2D, and central adiposity in risk of ischemic stroke. Furthermore, our results suggest that central adiposity may pose higher risk for stroke and CHD. Efforts to estimate the role of adiposity on CVD should consider the potential independent effects of different measures of adiposity.
